These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 31222709)

  • 1. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
    Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
    Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D; Sakamoto N; Takashima T; Takeda M; Pham QT; Ukai S; Maruyama R; Harada K; Babasaki T; Sekino Y; Hayashi T; Sentani K; Pommier Y; Murai J; Yasui W
    Cancer Sci; 2022 Feb; 113(2):784-795. PubMed ID: 34808009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy.
    Shee K; Wells JD; Jiang A; Miller TW
    PLoS One; 2019; 14(11):e0224267. PubMed ID: 31682620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High
    Onaga C; Tamori S; Motomura H; Ozaki A; Matsuda C; Matsuoka I; Fujita T; Nozaki Y; Hara Y; Kawano Y; Harada Y; Sato T; Mano Y; Sato K; Akimoto K
    Anticancer Res; 2021 Jan; 41(1):43-54. PubMed ID: 33419798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.
    Winkler C; Armenia J; Jones GN; Tobalina L; Sale MJ; Petreus T; Baird T; Serra V; Wang AT; Lau A; Garnett MJ; Jaaks P; Coker EA; Pierce AJ; O'Connor MJ; Leo E
    Br J Cancer; 2021 Mar; 124(5):951-962. PubMed ID: 33339894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition.
    Nagasawa S; Sedukhina AS; Nakagawa Y; Maeda I; Kubota M; Ohnuma S; Tsugawa K; Ohta T; Roche-Molina M; Bernal JA; Narváez AJ; Jeyasekharan AD; Sato K
    PLoS One; 2015; 10(2):e0118002. PubMed ID: 25679396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.
    Murai J; Thomas A; Miettinen M; Pommier Y
    Pharmacol Ther; 2019 Sep; 201():94-102. PubMed ID: 31128155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (
    Tang SW; Thomas A; Murai J; Trepel JB; Bates SE; Rajapakse VN; Pommier Y
    Clin Cancer Res; 2018 Apr; 24(8):1944-1953. PubMed ID: 29391350
    [No Abstract]   [Full Text] [Related]  

  • 10. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
    Zoppoli G; Regairaz M; Leo E; Reinhold WC; Varma S; Ballestrero A; Doroshow JH; Pommier Y
    Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15030-5. PubMed ID: 22927417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.
    Ballestrero A; Bedognetti D; Ferraioli D; Franceschelli P; Labidi-Galy SI; Leo E; Murai J; Pommier Y; Tsantoulis P; Vellone VG; Zoppoli G
    J Transl Med; 2017 Oct; 15(1):199. PubMed ID: 28969705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
    Li Y; Yang W; Yang Q; Zhou S
    Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer.
    Zhang B; Stewart CA; Wang Q; Cardnell RJ; Rocha P; Fujimoto J; Solis Soto LM; Wang R; Novegil V; Ansell P; He L; Fernandez L; Jendrisak A; Gilbertson C; Schonhoft JD; Byun J; Jones J; Anderson AKL; Aparicio A; Tran H; Negrao MV; Zhang J; Wang WL; Wistuba II; Wang J; Wenstrup R; Byers LA; Gay CM
    Br J Cancer; 2022 Aug; 127(3):569-576. PubMed ID: 35440668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq.
    Takashima T; Sakamoto N; Murai J; Taniyama D; Honma R; Ukai S; Maruyama R; Kuraoka K; Rajapakse VN; Pommier Y; Yasui W
    Virchows Arch; 2021 Mar; 478(3):569-579. PubMed ID: 32474729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers.
    Zhang B; Ramkumar K; Cardnell RJ; Gay CM; Stewart CA; Wang WL; Fujimoto J; Wistuba II; Byers LA
    Br J Cancer; 2021 Nov; 125(10):1333-1340. PubMed ID: 34294893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dephosphorylation activates the interferon-stimulated Schlafen family member 11 in the DNA damage response.
    Malone D; Lardelli RM; Li M; David M
    J Biol Chem; 2019 Oct; 294(40):14674-14685. PubMed ID: 31395656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer.
    Amara D; Wolf DM; van 't Veer L; Esserman L; Campbell M; Yau C
    Breast Cancer Res Treat; 2017 Jan; 161(1):41-50. PubMed ID: 27815749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transposon insertional mutagenesis in mice identifies human breast cancer susceptibility genes and signatures for stratification.
    Chen L; Jenjaroenpun P; Pillai AM; Ivshina AV; Ow GS; Efthimios M; Zhiqun T; Tan TZ; Lee SC; Rogers K; Ward JM; Mori S; Adams DJ; Jenkins NA; Copeland NG; Ban KH; Kuznetsov VA; Thiery JP
    Proc Natl Acad Sci U S A; 2017 Mar; 114(11):E2215-E2224. PubMed ID: 28251929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors.
    Tell RW; Horvath CM
    Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12787-92. PubMed ID: 25139989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.